Invention Grant
- Patent Title: Interferon alpha mutant and its polyethylene glycol derivative
- Patent Title (中): 干扰素α突变体及其聚乙二醇衍生物
-
Application No.: US13431226Application Date: 2012-03-27
-
Publication No.: US08901277B2Publication Date: 2014-12-02
- Inventor: Jinyi Liu , Xiaoxia Niu , Minyi Zhou , Yi Yang , Jianbo Sun , Yongqing Cheng
- Applicant: Jinyi Liu , Xiaoxia Niu , Minyi Zhou , Yi Yang , Jianbo Sun , Yongqing Cheng
- Applicant Address: CN Beijing CN Beijing
- Assignee: Beijing Tri-Prime Genetic Engineering Co., Ltd,Beijing Bio-Tech Development Co., Ltd.
- Current Assignee: Beijing Tri-Prime Genetic Engineering Co., Ltd,Beijing Bio-Tech Development Co., Ltd.
- Current Assignee Address: CN Beijing CN Beijing
- Agency: Scully, Scott, Murphy & Presser, P.C.
- Priority: CN200610167660 20061221
- Main IPC: C07K14/52
- IPC: C07K14/52 ; C12N15/00 ; A61K38/21 ; C07K1/00 ; C12P21/04 ; C07K14/56 ; A61K47/48 ; A61K38/00

Abstract:
IFN-alpha mutants are obtained by substituting Cys for Tyr at position 85 or 86 in existing IFN-alpha. Their polyethylene glycol derivatives with high in vitro antiviral activity and prolonged in vivo half-life are also provided, wherein a polyethylene glycol moiety is covalently bound to the free Cys residue of an IFN-alpha mutant. The preparation methods of PEG derivatives of IFN-alpha mutants and medical compositions comprising the derivatives are also provided. The test results showed that the IFN-alpha mutants of the present invention are ready to prepare and have high activity; their polyethylene glycol derivatives have extended lifetime in the body and low clearance rate.
Public/Granted literature
- US20130287733A1 INTERFERON ALPHA MUTANT AND ITS POLYETHYLENE GLYCOL DERIVATIVE Public/Granted day:2013-10-31
Information query